PielotaxПиелотакс
A peptide mixture from calf or pig kidneys, studied in a Russian report on kidney laboratory measures.
What the studies found
Comparison in people · 2011
Pielotax: clinical report on a tissue-derived preparation
- Blood urate in men
- 0.44 ± 0.02 mmol/L with Pielotax versus 0.56 ± 0.01 mmol/L with conventional care.
- Blood urate in women
- 0.37 ± 0.03 mmol/L with Pielotax versus 0.48 ± 0.02 mmol/L with conventional care.
- Residual nitrogen
- 27.1 ± 0.4 mmol/L with Pielotax versus 30.5 ± 0.6 mmol/L with conventional care.The table marks p < 0.05 versus conventional care.
After 30 days, blood urate was 0.44 versus 0.56 mmol/L in men and 0.37 versus 0.48 mmol/L in women, comparing adjunctive Pielotax with conventional treatment.
Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
Study notes · methods, sources and limitations
Participants or model Gouty nephropathy: 27 treated, 15 controls.
Design 42 participants with gouty nephropathy: 27 received one to two Pielotax capsules three times daily before meals for 30 days alongside conventional therapy, and 15 received conventional therapy. The report describes random assignment without explaining how it was performed.
Important limitations
- Sequence generation, concealment and long-term outcomes remain unresolved. Laboratory-marker changes do not establish prevention of kidney failure. Commercially reproduced institute report; independent peer review and independent replication are not established by this document. Short-term reporting without a complete adverse-event protocol cannot establish long-term safety. Preparation equivalence to current products or synthetic peptides is unproven.
- The report measured short-term laboratory markers and gives no detailed adverse-event assessment.
Institute clinical report (commercial reproduction); 2011 study/report date, not website publication date · Institute report — commercial reproduction
Animal research · 2015
Pielotax kidney peptide complex and three short peptides in cisplatin-treated rats
Findings for this preparation
Glomerular filtration was 433.3 µL/min with the kidney complex versus 240.8 with cisplatin alone.
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
Study notes · methods, sources and limitations
Participants or model 42 rats randomized to six equal groups of seven: intact control, cisplatin alone, or cisplatin with kidney complex, EDL, AED or AEDG.
Design Cisplatin-associated kidney injury with intact and injury controls. Urine was collected over two hours, 72 hours after cisplatin.
Important limitations
- Small rat arms and a pretreatment design. Clinical outcomes and the effects of marketed oral products were not measured. Each outcome applies to the specific arm and preparation tested.
Bulletin of Experimental Biology and Medicine. 2015;159(6):736–739. PMID 26515176. · Publication record
About Pielotax
Identity / background source ↗
Organ-derived peptide research: clinical findings and lineage ↗
Research background
Pielotax is a kidney-derived peptide complex. A clinical report measured renal markers in gouty nephropathy, and an animal study assessed renal function after cisplatin injury.
- Compound class
- Tissue-derived peptide preparation
- Research collection
- Peptide bioregulation · editorial grouping
- Institutions in linked studies
- St. Petersburg Institute of Bioregulation and Gerontology · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
- Source review
- Review dates and the material assessed are listed with each publication below.
Understanding the evidence
Human research
Gouty nephropathy: 27 treated, 15 controls.
Study methods
Small comparative institute report; allocation, blinding and outcome interpretation require caution
Independent replication
Independent replication not established in this collection
Source access
Report reproduction linked; source language and review scope shown per record
Safety evidence
Short-term reports do not establish long-term safety or equivalence to current products
Open a topic for the evidence assessment.
Findings by study
Tissue-preparation reports: comparisons, source limits and remaining gaps ↗
Animal research · 2015
Pielotax kidney peptide complex and three short peptides in cisplatin-treated rats
Glomerular filtration was 433.3 µL/min with the kidney complex versus 240.8 with cisplatin alone.
Study notes and original source
Pielotax kidney peptide complex and three short peptides in cisplatin-treated rats
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
Injected kidney polypeptide complex, identified as Pielotax in the Russian reproduction. EDL, AED and AEDG were separate short-peptide arms.
I. I. Zamorskii, T. S. Shchudrova, N. S. Lin’kova, T. E. Nichik, V. Kh. Khavinson · Bulletin of Experimental Biology and Medicine. 2015;159(6):736–739. PMID 26515176.
Filtration rates were 433.3 with the kidney complex, 543.9 with EDL, 305.1 with AED and 469.9 with AEDG versus 240.8 µL/min with cisplatin alone. AED did not significantly improve filtration.
Results and tables
Reported findings and study design
Cisplatin-associated kidney injury with intact and injury controls. Urine was collected over two hours, 72 hours after cisplatin.
Population or model 42 rats randomized to six equal groups of seven: intact control, cisplatin alone, or cisplatin with kidney complex, EDL, AED or AEDG.
Dose, route and schedule
Interventions were intraperitoneal once daily for four days before and three after cisplatin. Kidney complex 300 µg/kg, EDL 3 µg/kg, AED 3 µg/kg, AEDG 7 µg/kg. Cisplatin was a 6 mg/kg intraperitoneal injection 72 hours before sampling.
Protocol source ↗ · Original journal full text and Table 1. Russian reproduction identifies the branded kidney complex.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Glomerular filtration rate | 433.3 kidney complex, 543.9 EDL, 305.1 AED, 469.9 AEDG vs 240.8 µL/min with cisplatin alone | |
| Plasma creatinine | 67.43 with kidney complex vs 94.91 µmol/L with cisplatin alone | p≤0.05 |
| Diuresis over two hours | 2.62 kidney complex, 3.02 EDL, 1.81 AED, 2.89 AEDG vs 1.50 mL with cisplatin alone |
Selected Table 1 values
| Outcome | Intact | Cisplatin | Kidney complex | EDL | AED | AEDG |
|---|---|---|---|---|---|---|
| Filtration, µL/min | 502.90 | 240.8 | 433.3 | 543.9 | 305.1 | 469.9 |
| Creatinine, µmol/L | 64.90 | 94.91 | 67.43 | 68.95 | 82.60 | 77.54 |
| Urine over two hours, mL | 4.12 | 1.50 | 2.62 | 3.02 | 1.81 | 2.89 |
Source for these results ↗ · Reviewed 2026-11-14
- Population / setting
- 42 rats randomized to six equal groups of seven: intact control, cisplatin alone, or cisplatin with kidney complex, EDL, AED or AEDG.
- Source reviewed
- Original journal full text and Table 1. Russian reproduction identifies the branded kidney complex.
Study limitations
- Small rat arms and a pretreatment design. Clinical outcomes and the effects of marketed oral products were not measured.
- Each outcome applies to the specific arm and preparation tested.
Reviewed 2026-11-14.
Comparison in people · 2011
Pielotax: clinical report on a tissue-derived preparation
After 30 days, blood urate was 0.44 versus 0.56 mmol/L in men and 0.37 versus 0.48 mmol/L in women, comparing adjunctive Pielotax with conventional treatment.
Blood urate in men · 0.44 ± 0.02 mmol/L with Pielotax versus 0.56 ± 0.01 mmol/L with conventional care.
Study notes and original source
Pielotax: clinical report on a tissue-derived preparation
Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
Tissue-derived mixture / named preparation · Institute report — commercial reproduction
St. Petersburg Institute of Bioregulation and Gerontology Medical Center (report attribution) · Institute clinical report (commercial reproduction); 2011 study/report date, not website publication date
After 30 days, blood urate was 0.44 versus 0.56 mmol/L in men and 0.37 versus 0.48 mmol/L in women, comparing adjunctive Pielotax with conventional treatment.
Results and tables
Reported findings and study design
42 participants with gouty nephropathy: 27 received one to two Pielotax capsules three times daily before meals for 30 days alongside conventional therapy, and 15 received conventional therapy. The report describes random assignment without explaining how it was performed.
Population or model Gouty nephropathy: 27 treated, 15 controls.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Blood urate in men | 0.44 ± 0.02 mmol/L with Pielotax versus 0.56 ± 0.01 mmol/L with conventional care. | |
| Blood urate in women | 0.37 ± 0.03 mmol/L with Pielotax versus 0.48 ± 0.02 mmol/L with conventional care. | |
| Residual nitrogen | 27.1 ± 0.4 mmol/L with Pielotax versus 30.5 ± 0.6 mmol/L with conventional care. | The table marks p < 0.05 versus conventional care. |
The report measured short-term laboratory markers and gives no detailed adverse-event assessment.
Source for these results ↗ · Reviewed 2026-11-16
- Population / setting
- Gouty nephropathy: 27 treated, 15 controls.
- Source reviewed
- English compilation, PDF pages 43 onward; selected report text/tables checked. Russian original not reconciled.
Study limitations
- Sequence generation, concealment and long-term outcomes remain unresolved. Laboratory-marker changes do not establish prevention of kidney failure.
- Commercially reproduced institute report; independent peer review and independent replication are not established by this document.
- Short-term reporting without a complete adverse-event protocol cannot establish long-term safety. Preparation equivalence to current products or synthetic peptides is unproven.
Reviewed 2026-11-16.
Related compound research
Follow shared publications or research classes. These links do not establish equivalent effects between compounds.
Research collection curated by @PepMariner · editorial standards. Send a source correction ↗
Browse bibliography & PDFs ↗